Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Biopharmaceutical Process Analytical Technology Market Worth $2.6 billion |…
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=95920337 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=95920337 Browse in-depth TOC on "Biopharmaceutical Process Analytical Technology Market" 168 - Tables 52 - Figures 255 - Pages Biopharmaceutical Process Analytical Technology Market Scope: Liquid chrpmatography/HPLC segment to register significant growth rate over the forecast...
PR Newswire
14/05/2024
Department of Health - Abu Dhabi partners with GSK to Establish Regional Vaccine…
The key pillars of the collaboration are: the establishment of a regional vaccine distribution hub in Abu Dhabi; working together to maximise the strategic and healthcare impacts of the establishment of the GSK Vaccine Regional Distribution Hub; collaborating to ensure its successful establishment and operation; and exploration of opportunities to foster knowledge exchange and capability building through collaboration between GSK and the UAE; and jointly focusing on prevention strategies to…
PR Newswire
14/05/2024
Notification of managers' transactions
ANNOUNCEMENT NO. 264 Notification of managers' transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them.See the transactions of Vice-Chairman of the Board of Directors Martin Glensbjerg in the attached PDF document. For further information, please...
Nasdaq GlobeNewswire
14/05/2024
Genmab to Present New and Updated Results From Multiple Clinical Trials…
Media ReleaseCOPENHAGEN, Denmark; May 14, 2024 Sixteen abstracts accepted for presentation and publication demonstrate depth and breadth of comprehensive epcoritamab development programThree oral presentations highlight novel data evaluating epcoritamab in patients with relapsed/refractory (R/R) follicular lymphoma (FL), in combination for first-line treatment of diffuse large B-cell lymphoma (DLBCL), and in Richter's transformation (RT)Genmab A/S (Nasdaq:GMAB)...
Nasdaq GlobeNewswire
14/05/2024
Next Generation Sequencing Market to Reach $97.8 Billion, Globally, by 2035 at…
Request Sample of the Report on Next Generation Sequencing Market Forecast 2035 - https://www.alliedmarketresearch.com/request-sample/2048 Request Sample of the Report on Next Generation Sequencing Market Forecast 2035-https://www.alliedmarketresearch.com/request-sample/2048 Prime determinants of growth Growth in adoption of next generation sequencing, advancements in technologies and presence of key players are the factors that drive the growth of the global next generation...
PR Newswire
14/05/2024
Accumulus Synergy Sponsors Revolutionary Healthcare Data Standard, Advancing…
Nonprofit Industry Association, Accumulus Synergy, is the primary sponsor and funder of a newly published data standard that streamlines data exchange and contributes to a more connected and patient-centered healthcare ecosystem As the life sciences-regulatory industry continues its digital transformation journey, efficient data exchange remains a critical challenge. PQ content is reused throughout the medicinal product lifecycle accounting for the majority of information exchanged across...
Nasdaq GlobeNewswire
14/05/2024
Kohler Co. Captures Prestigious Honors in Global Design: Coveted Gold iF Design…
Creativity and leading-edge design are the heart and soul of the Kohler ethos and its teams of bold creators around the world are the foundation of some of the most iconic brands in home design. The company has forged a reputation for innovation, artistry, and design while also possessing an operating philosophy rooted in entrepreneurial spirit, tenacity, and humility. Creativity and leading-edge design are the heart and soul of the Kohler ethos and its teams of bold creators around the world...
PR Newswire
14/05/2024
HUB Organoids B.V. Awarded Frost & Sullivan's 2024 Technology Innovation…
As a pioneer in organoid technology, HUB offers transformative solutions to the pharmaceutical industry for more effective, faster, and ethical drug development. HUB develops disruptive PDOs that accurately replicate human drug responses compared to animal models and cell lines, greatly increasing the value and impact of drug development programs. As a pioneer in organoid technology, HUB offers transformative solutions to the pharmaceutical industry for more effective, faster, and ethical…
PR Newswire
14/05/2024
HealthTech Bioactives Partners with Abolis for Sustainable Production of…
The initial phase of the partnership will focus on developing two high-value molecules with limited sourcing availability. Up to eight additional molecules will be added to the development pipeline. This strategic collaboration aims to secure production, increase capacities, and reduce manufacturing costs compared to traditional extraction methods. The initial phase of the partnership will focus on developing two high-value molecules with limited sourcing availability. Up to eight additional...
PR Newswire
14/05/2024
Theriva™ Biologics to Participate in the A.G.P. Virtual Healthcare Conference
A.G.P. 2024 Virtual Healthcare ConferenceFormat: Fireside ChatPresentation Date: Tuesday, May 21, 2024 Presentation Time: 7:30 AM ET Webcast: ClickhereAbout Theriva™ Biologics, Inc. Theriva™ Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and...
Nasdaq GlobeNewswire
14/05/2024
Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in…
"This is a fantastic result from many years of dedication and hard work by teams from both companies and I am delighted that patients in China now can benefit from Nefecon, which has been specifically designed to address the origin of IgAN," said Renee Aguiar-Lucander, CEO. "This is a fantastic result from many years of dedication and hard work by teams from both companies and I am delighted that patients inChinanow can benefit from Nefecon, which has been specifically designed to…
PR Newswire
14/05/2024
Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at…
"Each year, the spring scientific meetings bring together critical stakeholders from across the field of psychiatry to share insights and advance patient care; Alkermes is honored to have our research selected for presentation at these important events," said Craig Hopkinson, M.D., Chief Medical Officer and Executive Vice President of Research & Development at Alkermes. "These data from across our psychiatry product franchise demonstrate our commitment to expanding the body of…
PR Newswire
14/05/2024
Immatics Announces First Quarter 2024 Financial Results and Business Update
Company Provides Clinical Data Update from Ongoing Phase 1 Clinical Trial withACTengine® IMA203 TCR-T Targeting PRAMEUpdated clinical data on ACTengine® IMA203 targeting PRAME in 30 heavily pre-treated metastatic melanoma patients at RP2D: 55% confirmed objective response rate, including tumor shrinkage achieved in 87% of patients; median duration of response of 13.5 months including 11/16 ongoing confirmed responses; IMA203 continues to maintain a favorable safety profile...
Nasdaq GlobeNewswire
14/05/2024
Natura and Avon Integration in Latam Continuing to Drive Healthier Profitability
At Natura &Co Latam, Q1-24 revenues grew 3.1% YoY in CC. Natura Brazil was again the highlight, reporting an 11.3% YoY increase in Q1-24 revenues, attesting strong momentum despite the tough comparative base from Q1-23 when the brand had achieved a 25% YoY growth rate in the region. This performance includes retail sales which showed robust growth in the country, fueled by solid same-store sales and a still strong pace of store openings. The brand opened 132 stores in the last twelve months…
PR Newswire
14/05/2024
MolecuLight Clinical Research Featured at the Upcoming SAWC Spring 2024…
"We are delighted to witness the ongoing surge in the adoption of our technology across the US and abroad, which has resulted in a significant presence at SAWC Spring, further confirming the value of MolecuLight as seen by clinicians", remarks Anil Amlani, CEO of MolecuLight. "The widespread adoption of MolecuLight can be attributed to the unique capability of our devices to accurately detect the location and load of bacteria that can lead to infections resulting in better patient…
PR Newswire
14/05/2024
Periodemeddelelse Første Kvartal 2024
Selskabet har opnået følgende resultat for første kvartal 2024: EBIT: negativt DKK 0.9 mio. De strategiske partnerskaber har bidraget med en indtægt på DKK 0.6 mio.Egenkapital ultimo marts 2024: DKK 13.4 mio. Business update: Datterselskaberne i Schweiz og USA er under likvidation, og det forventes fortsat at de begge er likvideret i H1 2024.Selskabet arbejder fortsat aktivt med værdiskabelsen i sin første strategiske investering i det børsnoterede svenske selskab CombiGene AB...
Nasdaq GlobeNewswire
14/05/2024
Chiesi Group Forges Alliance with Karolinska Institutet to Tackle Urgent Health…
Chiesi Group and KI will exchange ideas, expertise, and resources to accelerate the translation of scientific discoveries into tangible healthcare solutions. Their collaboration is underpinned by a shared commitment to advancing medical science and improving patient care through joint research, development, and innovation efforts. Chiesi Group and KI will exchange ideas, expertise, and resources to accelerate the translation of scientific discoveries into tangible healthcare solutions...
PR Newswire
14/05/2024
Ventricular Assisted Devices Market to Reach $4.1 Billion, Globally, by 2035 at…
Request Sample of the Report on Ventricular Assisted Devices Market Forecast 2035- https://www.alliedmarketresearch.com/request-sample/2024 Request Sample of the Report on Ventricular Assisted Devices Market Forecast 2035-https://www.alliedmarketresearch.com/request-sample/2024 Prime determinants of growth Rise in adoption of ventricular assisted devices, advancements in technologies, and presence of key players are factors that drive the growth of the global ventricular assisted...
PR Newswire
14/05/2024
Publication in Nature Immunology outlining the contribution of B cells to…
In cancer, Alchemab focuses on identifying antibodies from patients with certain solid tumors who are long-term survivors of the disease. In preliminary work, Alchemab has identified antibodies associated with checkpoint inhibition, angiogenesis, and cytokine modulation in cancer survivors. The opportunity to identify novel antibodies and targets associated with cancer survivors represents a unique approach to therapeutic development in oncology. In cancer, Alchemab focuses on identifying...
PR Newswire
14/05/2024
Coloplast expands its Luja™ portfolio with next generation catheter for women
The female intermittent catheter enables complete bladder emptying in one free flow 1, aiming to reduce the risk of urinary tract infections 2.Following the successful launch of Luja with Micro-hole Zone Technology, a next generation intermittent catheter for men, Coloplast is now launching Luja for women.“So far, we have received great feedback on Luja for men in our product evaluations. Nearly all healthcare professionals would recommend the male catheter to their patients 3, and...
Nasdaq GlobeNewswire
14/05/2024
Prestigious Colombian university hospital first to use Sectra's enterprise…
The solution was sold by Sectra's distribution partner in Colombia, Ajoveco, to Hospital Universidad del Norte located in Soledad, Metropolitan Area of the city Barranquilla in Atlántico. The hospital performs about 60,000 imaging exams a year, serving several cities in the North of Colombia and is in the forefront in terms of research and educational services in the country. The solution was sold by Sectra's distribution partner inColombia,Ajoveco, to Hospital Universidad del Norte...
PR Newswire
14/05/2024
Essity invests in new R&D center in France
"Essity's research and development is re-shaping paper making to contribute to a more sustainable and circular society, while improving people's hygiene and health. The new global R&D center in France, will enable us to continue to develop innovative new paper hygiene products and solutions that meet the needs and high expectations of customers and consumers," says Magnus Groth, President and CEO of Essity. "Essity's research and development is re-shaping paper making to…
PR Newswire
14/05/2024
Aino Health AB (publ): interim report january-march 2024
This document in English is a translation of the original in Swedish. In case of any discrepancy, the Swedish original will prevail.Extending existing contracts. Improved cash flow. January – March 2024 • Net sales were KSEK 5 994 (6 180) • Profit/loss after financial items was KSEK -2 943 (-2 791) • Earnings per share were SEK -0,0 (-0,1)Recently, we have seen growth within our customer network. I am delighted to announce that several of our existing customers have chosen to...
Nasdaq GlobeNewswire
14/05/2024
Implantica announces the eighth RefluxStop™ center of excellence in Italy
All four patients have recovered from surgery and are experiencing relief from the relentless symptoms of chronic GERD without PPI medication. All four patients have recovered from surgery and are experiencing relief from the relentless symptoms of chronic GERD without PPI medication. Prof. Agrusa offered, "I am proud to lead the way to a new standard in the surgical treatment of GERD for patients inSicily. Since RefluxStop™ does not encircle the food passageway, I can offer it to many...
PR Newswire
14/05/2024
Altri Comunicati
